Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
The Benefits of Group A Streptococcus NAAT
Labs that invested heavily in POC molecular tests during COVID-19 are well positioned to leverage this equipment toward GAS diagnostics
May 2024 Labs in Court
Recent enforcement actions and court cases include kickback schemes a-plenty and a reminder to focus on HIPAA compliance
Choosing and Using the Right Compliance Solution
Factors laboratories should consider when evaluating their compliance challenges, needs, and goals to select compliance solutions
Increasing Fees, Decreasing Access to Data in New CMS Proposal
New policies aim to better protect data against increasing cyberattacks, but academics say the changes will limit critical research
The Landscape of Laboratory Corruption
How widespread is corruption in the lab—and what can be done to combat it?
The Keys to a Successful Lab Partnership
This webinar will explore the benefits of strategic, deliberate partnerships in order to improve access to quality diagnostic laboratory services, support more timely answers to advance patient care, and serve as a defense mechanism against acquisition
Special Analysis: Two Key Legislative Initiatives Labs Should Know About
Though potential FDA LDTs regulation has drawn a lot of attention, other efforts could also have long-term effects on how labs do business.
Special Report: Will the COVID-19 Recovery Be Bumpier than Expected?
Though IVD and commercial lab Q3 2023 earnings reports held promising signs, Q4 2024 and FY2023 results tell a different story.
Dx Deals: Collaboration Takes Psoriasis Testing to New Level
Partnership between Mindera and PBM aims to optimize treatment matches for the disorder, as some drugs cost nearly six figures annually
FDA Watch: A New Blood Test for Accurate Alzheimer’s Detection
The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan